Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib

Annals of Hematology

Volumn 94, Issue 2, 2015, Pages 249-256

  Smith, David D ^a   Goldstein, Leanne ^a   Cheng, Mei ^b   James, Danelle F ^b   Kunkel, Lori A ^b   Fardis, Maria ^b   Hamdy, Ahmed ^c   Izumi, Raquel ^c   Buggy, Joseph J ^b   Clow, Fong ^b  

^a Division of Biostatistics   (United States)

^b PHARMACYCLICS INC   (United States)

^c Acerta Pharma   (United States)

Author keywords

B cell chronic lymphocytic leukemia; Bruton s tyrosine kinase; Chronic lymphocytic leukemia; CLL; Ibrutinib; Imbruvica; Kinase and phosphatase inhibitors; Leukemias and lymphomas; Lymphocytosis; Protein tyrosine kinases

Indexed keywords

IBRUTINIB; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABSOLUTE LYMPHOCYTE COUNT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG DOSE COMPARISON; HUMAN; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MULTICENTER STUDY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG RESISTANCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; OUTCOME ASSESSMENT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE;

AGED; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LINEAR MODELS; LYMPHOCYTE COUNT; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); PYRAZOLES; PYRIMIDINES;

EID: 84925462819     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2187-9     Document Type: Article

References (17)

1. Spaargaren M, Beuling EA, Rurup ML et al (2003) The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J Exp Med 198:1539–1550
2. de Gorter DJ, Beuling EA, Kersseboom R et al (2007) Bruton’s tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 26:93–104
3. Koopman G, Keehnen RM, Lindhout E et al (1994) Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol 152:3760–3767
4. de Rooij MF, Kuil A, Geest CR et al (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11):2590–2594
5. Herman SE, Niemann CU, Farooqui M et al (2014) Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. Leukemia
6. Rossi D, Gaidano G (2014) Lymphocytosis and ibrutinib treatment of CLL. Blood 123:1772–1774
7. Cheson BD, Bennett JM, Grever M et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990–4997
8. Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446–5456
9. Hallek M, Cheson BD, Catovsky D et al (2012) Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes (e-letter, published 04 June 2012). Blood 111:5446–5456
10. National Comprehensive Cancer Network (2012) NCCN Guidelines for Non-Hodgkin’s Lymphomas http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf
11. Byrd JC, Furman RR, Coutre SE et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32–42
12. Wang ML, Rule S, Martin P et al (2013) Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. The New England journal of medicine
13. Ponader S, Chen SS, Buggy JJ et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119:1182–1189
14. Advani RH, Buggy JJ, Sharman JP et al (2013) Bruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31:88–94
15. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Autom Control 19:716–723
16. Hurvich CM, Tsai C-L (1989) Regression and time series model selection in small samples. Biometrika 76:297–307
17. Burham KP, Anderson DR (2002) Model selection and multimodel inference: a practical information-theoretic approach. Springer